A 60-year-old female residing in Europe has been grappling with glioblastoma multiforme (GBM). In March 2021, following brain surgery, she commenced her chemotherapy with temozolomide and radiation therapy regimen. Unfortunately, her condition deteriorated by June 2021, her oncology then put her on bevacizumab (10mg/m2, q:14 days). Despite this intervention, progression persisted, leading to her being in a bedridden and wheelchair-dependent state by October 2021.
一位60岁的居住在欧洲的女性一直在与多形性胶质母细胞瘤（GBM）作斗争。在2021年3月，经过脑部手术后，她开始了她的替莫唑胺化疗和放射疗法治疗方案。不幸的是，到了2021年6月，她的病情恶化，她的肿瘤科医生随后将她转为贝伐单抗治疗（10mg/m2，q:14天）。尽管采取了这一干预措施，病情仍然恶化，导致到了2021年10月，她变得卧床不起，依赖轮椅。
The turning point in this challenging journey came when the patient was referred to combine ECCT with Bevacizumab by her oncology in Combating GBM. She undergoes ECCT treatments five days a week and at the same time continued bevacizumab therapy. She finally yielded astounding results. An MRI unveiled a notable reduction in tumor size and edema, instilling newfound hope in the face of this aggressive cancer.
在这艰难的旅程中的转折点是，患者被推荐由她的肿瘤科医生进行联合ECCT和贝伐单抗治疗。她每周接受5天的ECCT治疗，同时继续贝伐单抗治疗。最终，这种治疗取得了惊人的效果。核磁共振成像显示肿瘤体积和水肿显著减小，为这种侵袭性癌症带来了新的希望。
Even more promising was the sustained positive response observed two months into the ECCT and bevacizumab combination therapy. The tumor continued to exhibit signs of regression, offering a beacon of hope for the patient and her family.
更令人鼓舞的是，在进行了两个月的ECCT和贝伐单抗联合疗法后，肿瘤持续呈现出积极的反应，为患者和她的家人提供了一线希望。
After a dedicated four-month course of ECCT with bevacizumab, the mass lesion's size had significantly diminished. She extends her gratitude to the medical professionals and researchers instrumental in developing this groundbreaking treatment. The family expresses profound gratitude for the transformative impact of ECCT and bevacizumab on her. The transition from a bedridden, wheelchair-dependent state to a significantly improved quality of life, success not only extended the patient's life but also restored a semblance of normalcy and independence.
在经过了四个月的ECCT和贝伐单抗的专注治疗后，肿瘤的体积明显减小。她对参与开发这一突破性治疗方法的医疗专业人士和研究人员表示感激。这家庭对ECCT和贝伐单抗对她的健康所产生的转变表示深深的感激。从卧床不起、依赖轮椅的状态过渡到显著改善的生活质量，这一成功不仅延长了患者的生命，还恢复了一种正常和独立的状态。
Comments